IO Biotech stock downgraded to Neutral by H.C. Wainwright on trial delays
NegativeFinancial Markets

IO Biotech's stock has been downgraded to Neutral by H.C. Wainwright due to delays in clinical trials. This decision reflects concerns about the company's progress and could impact investor confidence. The trial delays may hinder IO Biotech's ability to bring its products to market, which is crucial for its growth and success in the competitive biotech industry.
— Curated by the World Pulse Now AI Editorial System